Kymera Therapeutics (KYMR) Total Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Total Liabilities data on file, last reported at $129.4 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $129.4 million, down 2.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $129.4 million (down 2.04% YoY), and the FY2025 annual result was $163.1 million, up 14.56% from the prior year.
• Total Liabilities fell to $129.4 million in Q1 2026 per KYMR's latest filing, from $163.1 million in the prior quarter.
• Over five years, Total Liabilities peaked at $180.8 million in Q4 2023 and troughed at $113.0 million in Q4 2022.
• A 5-year average of $144.5 million and a median of $142.4 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities dropped 29.04% in 2022, then soared 60.01% in 2023.
• A 5-year view of Total Liabilities shows it stood at $113.0 million in 2022, then soared by 60.01% to $180.8 million in 2023, then slipped by 21.22% to $142.4 million in 2024, then gained by 14.56% to $163.1 million in 2025, then decreased by 20.7% to $129.4 million in 2026.
• Business Quant data shows KYMR's Total Liabilities at $129.4 million in Q1 2026, $163.1 million in Q4 2025, and $155.8 million in Q3 2025.